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Abstract
The main problems in neurogenic voiding dysfunction (NVD) are failure to 
store, failure to empty, and combined failure to store and empty. The man-
agement priorities in NVD should be as follows, in order: (1) preservation of 
renal function, (2) freedom from urinary tract infection, (3) efficient blad-
der emptying, (4) freedom from an indwelling catheter, (5) patient satis-
faction with voiding management and (6) avoiding medication after proper 
management. Management of the urinary tract in patients with spinal cord 
injury must be based on urodynamic findings rather than inferences 
from a neurologic evaluation. Selecting high-risk patients is important to 
prevent renal function impairment in patients with chronic NVD. Patients 
with NVD should be regularly followed-up for lower urinary tract dysfunc-
tion using urodynamic study and any urological complication should be 
adequately treated. Avoiding a chronic indwelling catheter can reduce the 
incidence of developing a low compliant bladder. Intravesical instillation 
of vanilloids or injection of BOTOX provides an alternative treatment for 
refractory detrusor overactivity or low compliant bladder and can replace 
the need for bladder augmentation. When surgical intervention is necessary, 
a less invasive type of surgery and a reversible procedure should be con-
sidered first and unnecessary surgery in the lower urinary tract should be 
avoided. Keeping the bladder and urethra in good condition without inter-
fering with neuromuscular continuity will give patients with NVD a chance 
to benefit from new technologies in the future. It is most important that 
the physician continues to try to improve the quality of life of patients with 
NVD. [Tzu Chi Med J 2008;20(1):35–39]
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1. Introduction
Neurogenic voiding dysfunction (NVD) includes dys-
function of the urinary bladder and urethra due to 
central nervous system or peripheral neurogenic 
lesions. Cerebrovascular accidents, Parkinson’s dis-
ease, cerebral palsy, multiple sclerosis, transverse 
myelitis and spinal cord lesions can all result in NVD. 
Among all disorders resulting in NVD, spinal cord 
injury (SCI) remains the most difficult to manage. In 
patients with a single level SCI, a significant associa-
tion between the level of injury and the type of void-
ing dysfunction has been noted. Management of the 
urinary tract in patients with SCI must be based on 
urodynamic findings rather than inferences from a 
neurologic evaluation [1].
The main problems in NVD are: (1) failure to store 
due to detrusor hyperreflexia (DH) or urethral incom-
petence, (2) failure to empty due to detrusor are-
flexia, bladder neck dysfunction (BND) or detrusor 
sphincter dyssynergia (DSD), and (3) combined fail-
ure to store and empty due to DSD or detrusor hyper-
activity and impaired contractility.
The management priorities in NVD should be as fol-
lows, in order: (1) preservation of renal function, (2) 
freedom from urinary tract infection, (3) efficient blad-
der emptying, (4) freedom from an indwelling catheter, 
(5) patient satisfaction with voiding management and 
(6) avoiding medication after proper management.
2. Selecting high-risk patients
It is important to screen patients at high risk, such as 
those with a complete neurological lesion, cervical 
spinal cord paraplegia, a prolonged indwelling cath-
eter, a high detrusor leak-point pressure, DSD and 
autonomic dysreflexia (AD), a large postvoid residual 
and vesicoureteral reflux. Correction of urological 
complications and improvement in the quality of life 
are the two main goals for management of NVD. In 
addition, individualized treatment strategies for each 
patient should be developed and carefully evaluated.
3. Conservative management of NVD
Conservative management is the mainstay of uro-
logical treatment for NVD if possible. Patients can be 
instructed to void by abdominal stimulation, the Crede 
maneuver or abdominal straining. If they cannot have 
a balanced bladder after training, clean intermittent 
catheterization (CIC), performed either by themselves 
or a caregiver, is necessary. Spontaneous voiding with 
and without triggered voiding and/or bladder expres-
sion has proven to be less safe except in well-defined 
patients with regular urological follow-up [2]. Long-term 
indwelling catheters should be avoided except for 
patients with tetraplegia and those who are bed-
bound, in whom an indwelling urethral Foley catheter 
or suprapubic cystostomy may be an alternative.
4.  Intravesical treatment of DH
Medications to reduce DH by anti muscarinics [3], 
BND by alpha-blockers, and striated sphincter spas-
ticity by skeletal muscle relaxants or nitric oxide 
donors [4] and to increase detrusor muscle tone 
by choli nergic agents (Urecholine) are commonly 
prescribed to achieve better bladder control or effi-
cient emptying. However, patients with NVD might 
not be controlled without combined medication for 
detrusor dysfunction and bladder outlet resistance. A 
combination of alpha-adrenergic blockers and antimus-
carinic agents would be expected to be more benefi-
cial than the use of either one alone for the treatment 
of voiding dysfunction [5]. However, adverse effects 
increase in association with the number of medica-
tions used. Therefore, intravesical treatment of NVD 
will become the future treatment strategy for DH. 
Intravesical instillation of capsaicin or resiniferatoxin 
can successfully eradicate incontinence due to DH 
and can be considered a second line treatment for 
NVD [6–8]. In one study, DH decreased and urinary 
continence improved for 3–6 months after a single 
intravesical instillation of capsaicin. Patients treated 
with intravesical instillation of resiniferatoxin fared 
better than those treated with capsaicin, mainly 
because of less irritation and a longer duration of 
effects. For treatment of high level SCI and DSD, a 
dose of 10 µM was necessary to achieve better thera-
peutic results. However, the high concentration of 
intravesical vanilloid might induce AD during intra-
vesical instillation and this has limited this treatment 
in the clinical trial stage [9].
5. Surgical management of NVD
For patients who do not receive any therapeutic effects
from medical treatment or intravesical vanilloid instil-
lation, surgical intervention is mandatory to treat uro-
logical complications and preserve renal function. 
A transurethral external sphincterotomy provides sig-
nificant reduction of voiding pressure and AD in male 
SCI patients. The high systolic and diastolic blood 
pressure and postvoid residual decrease after sphinc-
terotomy [10]. Transurethral incision of the bladder 
neck can also reduce AD and facilitate spontaneous 
voiding in incomplete cervical SCI patients [11]. In 
tetraplegic patients, a urethral stent implant can 
relieve urethral resistance and facilitate spontaneous 
voiding; however, patients should be monitored for 
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possible stent erosion or migration. In one study, the 
most common stent complication was displacement, 
followed by stenosis, lithiasis and intraprosthetic 
calcification. In all, 8.5% of patients required stent 
removal [12]. In another study, bladder augmentation 
either by a segment of intestine, or autoaugmentation 
using a myomectomy resulted in a large capacity, low 
intravesical pressure and a non-reflux condition. Most 
patients reported no significant change in bowel func-
tion and nearly all patients expressed extreme sat-
isfaction with urological management [13]. However, 
long-term complications such as stone formation, 
loose stool, metabolic acidosis and chronic urinary 
tract infection remain to be solved [14]. In patients with 
cervical SCI or severe urethral sphincter deficiency, 
a continent lower urinary tract reconstruction (such 
as a Kock pouch) or closure of the bladder neck plus 
continent ileostomy and bladder augmentation might 
help the patient become continent by evacuation of 
the bladder by clean intermittent self-catheterization
from an ileostoma [15].
6.  Bladder and urethral neurotoxin 
injections
Future treatment strategies for NVD should include less 
invasive and reversible procedures such as neurotoxin
injections into the detrusor or urethral sphincter for 
bladder control and emptying. Intravesical botulinum 
toxin-A (BOTOX or Dysport) injection has been dem-
onstrated to be effective in restoration of urinary con-
tinence for up to 9 months [16–18]. This treatment is 
also effective in treating children with myelomenin-
gocele with detrusor hyperreflexia and incontinence 
[19,20]. Repeated BOTOX detrusor injections seem to 
be as effective as the first injection [21]. In one study,
BOTOX significantly reduced the maximum pres-
sure of uninhibited detrusor contractions compared 
to resiniferatoxin at all follow-up time points [22]. 
Urethral BOTOX injection not only reduces urethral 
resistance in patients with DSD or AD [23], it also pos-
sibly aids the early return of detrusor contractility 
in patients with urethral sphincter pseudodyssyner-
gia due to cerebrovascular accidents or Parkinson’s 
disease [24].
7. Renal function preservation
Renal function is also an important issue in the man-
agement of NVD, especially in chronic SCI patients. 
Patients with DSD, low compliant bladder and high 
intravesical pressure at end-bladder filling may be at 
high risk of renal failure. The incidence of chronic 
renal disease in patients with paraplegia and neural 
tube defects is higher than in the general population 
[25]. Bladder management affects bladder compli-
ance and changes in compliance with time. Patients 
using intermittent catheterization have a significantly 
higher incidence of normal compliance than those 
with Foley catheter management. Low bladder com-
pliance is statistically associated with vesicoureteral 
reflux, radiographic upper tract abnormality, pyelone-
phritis and upper tract stones. CIC is the superior 
method for preserving bladder compliance and pre-
venting upper tract complications associated with 
low compliance [26]. Patients with DSD who are 
currently using an indwelling catheter, performing 
CIC or spontaneously voiding should be monitored 
annually to prevent renal failure. Oral antimuscarinic 
agents or intravesical BOTOX injec tions might pro-
vide a low-pressure bladder and preserve renal func-
tion in the long-term management of NVD.
8. Quality of life issues
Quality of life (QoL) issues are also important in the 
treatment strategy for NVD. NVD patients’ willingness 
to use a management modality, their hand function 
and self-care capability, socioeconomic support, and 
family support should be taken into consideration in 
management. Patients with neurogenic detrusor over-
activity have reported a high rate of satisfaction with 
intravesical BOTOX injection [27]. However, more 
than 70% of patients need CIC to evacuate their 
bladder [28]. This treatment might not be accepted 
by patients in Asian countries as their environment 
and social support are not as good as those in Western 
countries [29]. When performing BOTOX injections 
for patients with DSD, injection into the detrusor or 
urethra should be carefully evaluated before treat-
ment. In an unpublished study, SCI patients who 
received intravesical BOTOX had more improve-
ment in QoL than those who received injections of 
BOTOX in the urethral sphincter. Reducing the dose 
of BOTOX or combined detrusor and urethral BOTOX 
injections might provide more therapeutic satisfac-
tion in patients who wish to preserve spontaneous 
voiding and experience less incontinence.
9. Future technologies
Finally, many novel therapeutic trials of treatment for 
SCI and NVD have emerged in recent decades. Repair 
of spinal cord trauma with nerve grafts and stabilizing 
the grafted area with fibrin glue containing acid fibro-
blast growth factor have succeeded in treating chronic 
paraplegia [30]. Transplants of fibroblasts express-
ing BDNG and NT-3 were applied in an animal SCI 
model with improvement in both bladder and hind-limb 
function, which was associated with reorganization 
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of spinal circuitry [31]. Using immortalized neural 
stem cells transplanted into the injured spinal cord 
promoted recovery of voiding function in the rat [32]. 
Direct re-establishment of a somatoautonomic reflex 
pathway to re-innervate the neurogenic bladder has 
been successful in children with myelodysplasia [33]. 
Nerve cross-over surgery for a neurogenic bladder, 
which is done by cutting the proximal portion of the 
S2-S3 roots and creating an end-to-end ana stomosis 
to the intercostal nerves, can restore central connec-
tions to the bladder [34]. Using intermittent electrical 
stimulation of the pudendal nerve or sacral anterior 
root stimulation are alternative treatments for detru-
sor areflexia or DSD [35–37]. Using bladder acellular 
matrix grafts might be a choice for bladder augmen-
tation to improve bladder capacity in spinal cord 
injury-induced neurogenic bladder [38,39]. All these 
technical advancements show that neurogenic voiding 
dysfunction can be adequately treated in the future.
10. Rational treatment strategies for NVD
Patients with NVD should be regularly followed-up to 
evaluate lower urinary tract dysfunction, and any uro-
logical complication should be adequately treated. 
Avoiding a chronic indwelling catheter can reduce 
the incidence of a low compliant bladder. Intravesical 
instillation of vanilloids or BOTOX injection provides 
an alternative treatment for refractory detrusor over-
activity or low compliant bladder, and can replace the 
need for bladder augmentation. When surgical inter-
vention is necessary, a less invasive type of surgery 
and a reversible procedure should be considered first 
and unnecessary surgery of the lower urinary tract 
should be avoided. Keeping the bladder and urethra 
in good condition without interfering with neuromus-
cular continuity will give patients with NVD a chance 
to benefit from new technologies in the future. It is 
most important that the physician continues to try to 
improve the quality of life of patients with NVD.
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